A Dose Ranging Study of the Effects of Macroflux PTH Compared With Macroflux Placebo and FORTEO in Postmenopausal Women With Osteoporosis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Teriparatide (Primary) ; Teriparatide
Indications Postmenopausal osteoporosis
Focus Therapeutic Use
Sponsors Zosano Pharma

Most Recent Events

01 Jan 2010 Results published in Journal of Clinical Endocrinology and Metabolism.
10 Nov 2009 Primary endpoint 'Lumbar spine bone mineral density' has been met.
10 Nov 2009 Results have been published in the current issue of the Journal of Clinical Endocrinology and Metabolism. The article is currently available online and will be in the January 2010 issue; announced by Zosano in a media release.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight